Proteostasis Therapeutics Inc (NASDAQ:PTI) shares traded up 6.2% during mid-day trading on Thursday . The stock traded as high as $5.50 and last traded at $5.33. 2,206,400 shares traded hands during mid-day trading, an increase of 489% from the average session volume of 374,374 shares. The stock had previously closed at $5.02.
Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a research report on Tuesday. Leerink Swann increased their price target on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a research report on Tuesday, December 12th. Robert W. Baird increased their price target on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th.
Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.16. The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. analysts forecast that Proteostasis Therapeutics Inc will post -2.47 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of PTI. LMR Partners LLP acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at approximately $127,000. Jennison Associates LLC increased its holdings in shares of Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after purchasing an additional 120,575 shares in the last quarter. FMR LLC increased its holdings in shares of Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after purchasing an additional 66,111 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at approximately $296,000. Finally, Bain Capital Public Equity Management LLC acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at approximately $1,233,000. 68.03% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/21/proteostasis-therapeutics-pti-trading-6-2-higher.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.